Evaluating the Role of Surgery in Mesothelioma: The MARS2 Trial

Encorafenib plus binimetinib demonstrated antitumor activity in patients with treatment-naive BRAF V600E-mutant advanced non–small cell lung cancer.

In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.

Zipalertinib appeared safe and effective in the treatment of heavily pretreated patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed on or after amivantamab.

In season 4, episode 13 of Targeted Talks, Benny Weskler, MBA, MD, FACS, FACCP, discusses neoadjuvant therapy for patients with non–small cell lung cancer.

A study found that reducing the dose of pembrolizumab in patients with advanced stage non–small cell lung cancer did not significantly affect overall survival compared to the standard dose.

The combination of belrestotug and dostarlimab significantly improved response rates in patients with previously untreated non–small cell lung cancer when compared to dostarlimab alone.